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Aim: To develop a decisional tool to identify the most cost-effective process flowsheets 
for allogeneic cell therapies across a range of production scales. Materials & 
methods: A bioprocess economics and optimization tool was built to assess competing 
cell expansion and downstream processing (DSP) technologies. Results: Tangential 
flow filtration was generally more cost effective for the lower cells/lot achieved in 
planar technologies and fluidized bed centrifugation became the only feasible option 
for handling large bioreactor outputs. DSP bottlenecks were observed at large 
commercial lot sizes requiring multiple large bioreactors. The DSP contribution to the 
cost of goods/dose ranged between 20–55%, and 50–80% for planar and bioreactor 
flowsheets, respectively. Conclusion: This analysis can facilitate early decision-making 
during process development.
Keywords: allogeneic cell therapy manufacture • bioprocess economics • centrifugation  
• downstream processing • filling • tangential flow filtration
Allogeneic stem cells are showing clinical 
promise in several therapeutic indications, 
with regional approvals for graft-versus-host 
disease (GvHD; Prochymal®, Osiris) and 
osteoarthritis (Cartistem®, Medipost). Advan-
tages of allogeneic cell therapies include being 
sourced from a healthy donor, which makes it 
more possible to scale-up rather than scale-out 
and cryopreserve the cell-based product for 
short-term storage and multidosing [1]. Hence 
it is possible to envisage allogeneic therapies 
following a product-driven, off-the-shelf busi-
ness model. Yet, several cell therapy products 
have experienced manufacturing challenges 
upon scale-up leading to processes with high 
cost of goods (COG) and high process vari-
ability [2–4]. This has triggered increasing 
interest in estimating manufacturing costs 
and identifying opportunities for cost reduc-
tion. Simaria et al. present a detailed process 
economics analysis for cell expansion that 
predicted dose–demand combinations when 
planar technologies would cease to be feasible, 
as well as target performance capabilities of 
microcarrier-based systems for the industry 
to be sustainable for high-demand, high-dose 
(109 cells/dose) scenarios [5]. The commercial 
feasibility of cell therapies for large commercial 
lot sizes (e.g., 1012 cells/lot) will depend not 
only on the technology capabilities for expan-
sion but also on commercially available tech-
nologies for downstream processing that are 
capable of handling this high cell load. This 
article presents a decisional tool to investigate 
the impact of commercial doses, demands and 
lot sizes on the cost–effectiveness of scalable, 
single-use downstream processing and fill 
finish technologies for cell therapies.
Figure 1 illustrates a typical cell therapy 
process flowsheet for allogeneic cell thera-
pies. Cell expansion is performed using 
either planar technologies such as T-flasks 
or multi-layer stacked vessels (e.g., Cell 
Factories [Nunc, ThermoFischer Scientific, 
MA, USA], Cell-STACKs or HYPERstacks 
[Corning Incorporated Life Sciences, MA, 
USA]) or via 3D microcarrier-based culture in 
single-use bioreactors. Following enzymatic 
treatment (e.g., trypsinization) to release the 
adherent cells, the downstream processing 
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(DSP) stages comprise microcarrier removal, where 
relevant, and volume reduction (VR) for concentration 
and washing of the cells. This is followed by formula-
tion into the cryopreservation buffer, vial filling and 
cryopreservation.
Some cell therapy manufacturing processes include 
downstream processing and fill finish technologies 
that are not amenable to scale-up such as benchtop 
centrifuges for volume reduction and manual filling 
in laminar air flow cabinets. However, this quickly 
Figure 1. Cell therapy manufacturing flow chart.
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becomes impractical for large commercial lot sizes for 
some high dose, large commercial demand indications. 
There are a limited number of DSP technologies that 
have been purpose designed to meet the specific needs 
of allogeneic cell therapy manufacturing at large scale. 
These requirements include minimal processing time, 
achieving high concentration factors while preserving 
high cell viabilities, integrating volume reduction and 
washing to reduce impurity levels to <1 ppm [6] and 
providing a low-shear processing environment. Fur-
thermore, technologies need to be closed, automated, 
scalable and employ single-use components; the latter 
of which has the added potential benefits of reducing 
turnaround time and cost of goods [7].
Early downstream processing efforts focused on 
adapting technologies utilized within the blood prod-
uct processing industry to use single-use components 
for washing and concentration of cell therapy products 
at a small scale. Examples include the COBE 2991 
(Terumo BCT, CA, USA) operating via density gra-
dient centrifugation or Elutra Cell separation systems 
(Terumo BCT) which operate in fluidized bed centrif-
ugation mode. However, the scale of these systems is a 
limitation as less than a liter can be processed per cycle. 
Other commercially available, continuous centrifuga-
tion-based systems such as the Carr Centritech Cell II 
or Unifuge allow for larger process volumes but may 
not easily integrate the washing step [8]. At commercial 
scales, handling harvest volumes of 100–1000s l per lot, 
it is necessary to consider more scalable technologies 
for volume reduction and washing. Hence this work 
focused on DSP technologies which were not only 
single-use, closed and automated but also scalable and 
with which experience in the commercial cell therapy 
industry was already available. These options include 
tangential flow filtration (TFF) and fluidized bed cen-
trifugation (FBC). TFF is most commonly used in the 
protein or antibody industry for concentration or buf-
fer exchange, and can also be optimized to work for 
cell therapy processes. During TFF, recirculation of the 
feed across the membrane surface minimizes filter foul-
ing and also allows washing to be achieved when oper-
ated in diafiltration mode. Lonza (MD, USA) has opti-
mized the TFF process set-up and operating conditions 
for both VR and washing of therapeutic cells (PCT 
Publication number WO2011091248 A1 [9]). The filter 
used is a hollow fiber filter. These filters generally pos-
sess a lower hold-up volume compared with flat sheet 
membrane cassettes and are available in ready-to-use 
presterilized formats by companies such as GE Health-
care [8]. Low shear, specifically a shear rate of less than 
4000 s-1 (PCT publication number WO2011091248 
A1 [9]), in these systems can be achieved by optimizing 
key process parameters such as the recirculation flow 
rate. Real-time monitoring of transmembrane pressure 
is also enabled by the incorporation of single-use pres-
sure sensors. Gamma-irradiated bags, filters and tubing 
in addition to aseptic connectors such as GE Health-
care’s Readymate™ connections and sterile tube weld-
ing reduce the risk of contamination.
FBC systems, such as the kSep® (KBI Biopharma, 
NC, USA), operate via counter-flow centrifugation, 
to provide a low shear environment for the cells. The 
opposing forces of fluid flow and centrifugal force 
result in the formation of a fluidized bed of cells, which 
allows for both volume reduction and washing, clear-
ing residuals such as serum albumin from the media. 
These systems have a varying total single-use chamber 
capacity from 400 ml to 6 l [10] that can potentially 
handle 10–100s l from the expansion stage.
At small-scale, microcarrier beads are normally 
separated from cells by sieving post-trypsinization. At 
medium-to-large scale, systems to separate viable cells 
from microcarriers at larger volumes are under develop-
ment. The difference in size and density between cells 
and microcarriers can be utilized for the separation of the 
latter using fluidized bed centrifugation such as kSep. 
Similarly, TFF using hollow fiber filters of the appropri-
ate pore size can also be used for microcarrier removal. 
In addition, it would be advantageous to perform micro-
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Figure 2. Cell expansion and volume reduction optimization framework. 
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carrier removal and VR and cell washing using the 
same technology so as to minimize losses between steps. 
More recently, alternative technologies for microcarrier 
separation are being developed, which include Pall Solo-
hill’s cell separation bag containing a 70 μm screen and 
Thermoscientific’s HyQ Harvestainer [11].
Since allogeneic cell therapies are most commonly 
stored in cryovials and cryopreserved, a range of auto-
mated vial filling machine scales were also investigated 
in this study. Following thawing of the cryopreserved 
product, in the clinic, the therapeutic cells should have a 
minimum viability of 70% (preferably more than 85%), 
and a recovery of greater than 80% of viable cells [8] . A 
typical final product concentration is around 10 million 
cells/ml (the focused target of this study) [8], with the 
majority of products in the 5 million cells/ml to 25 mil-
lion cells/ml range, as required, for example, for aggra-
vated rheumatoid arthritis or GvHD disease, respec-
tively (clinical trials identifier: NCT01663116 [12], and 
identifier NCT00823316 [13], assuming administration 
of 4–20 ml and an average patient weight of 100 kg). 
Vial filling at scale is likely to be carried out via large-
scale automated fill lines such as the Crystal® Px sys-
tem from Aseptic Technologies. Cryo freezers for cell 
therapies allow for controlled-rate freezing and uniform 
freezing profiles, where cells are stored in the vapor 
phase of liquid nitrogen. This together with subsequent 
cold-chain management should enhance cell viability 
and quality for the product.
To date, published cost studies for cell therapy bio-
processing have focused solely on expansion options 
[5,14]. On the downstream front, Pattasseril et al. dis-
cussed the process limitations of traditional VR tech-
nologies used for cell therapy processing, and the 
potential capabilities of more scalable technologies that 
are being adapted for cell therapies [8]. However, there 
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are no detailed cost studies published on downstream 
processing decisions for cell therapies. In this article, 
an integrated decisional tool incorporating bioprocess 
economics and optimization for addressing cell ther-
apy downstream processing challenges is described. 
This article builds on the decisional tool described 
in [5] to capture the mass balances, equipment sizing, 
process economics and optimization algorithms for 
both the expansion and downstream processing stages 
of cell therapy bioprocesses. It describes the extension 
of the tool to model the distinctive features of each of 
the downstream processing stages so as to determine 
their cost–effectiveness for both planar and microcar-
rier-based flowsheets. The effect of scale and level of 
demand on optimal DSP technologies are investigated, 
highlighting the current technology limits and identi-
fying where improvements in technologies are required 
to cope with larger future likely demands.
Table 1. Key process and cost assumptions used in the case study.
Step Vessel type Million cells  
out/unit
Volume out (l)
Expansion L-10; L-40 159; 636 0.48; 1.91
 cL-12; cL-36; cL-120 150; 450; 1500 0.40; 1.2; 3.6
 MC-500; MC-1000; MC-2000 173,053; 346,106; 
692,213
375; 750; 1500
Step Process parameter Value
Microcarrier removal Step yield (%) 90
 Number of microcarriers/g 4.6 × 105
 Diameter of a single microcarrier (μm) 150
 Number of operators/unit 2
Volume reduction Step yield (%) 85
 Maximum time (h) 4 
 Target final product concentration (in the vial;  
million cells/ml)
10 
 Number of washes in volume reduction step 8
 Number of operators/unit 2
Cryopreservation and filling Step yield (%) 80
 Maximum time (h) 2
 Number of operators/unit 2
 Volume ratio of cells to DMSO 1:1
 Volume cryovial (ml) 6
Category Cost parameter Value
Materials FBC single-use kit (FBC-A to FBC-B) US$1800/4ch (A), US$8000/6ch (B) 
 TFF membrane (TFF-A to TFF-F) US$1027 (A), US$1560 (B), US$1560 
(C), US$2147 (D), US$3306 (E), 
US$3306 (F)
 Cryovial US$3/cryovial
Other QC (assumed split equally across expansion, volume 
reduction and cryopreservation)
US$10,000/lot
 Depreciation period (years) 7
 Lang factor 23.67
 Maintenance (% FCI) 10
 Depreciation (% FCI) 7
Volume out of planar vessels equals volume post trypsinization (1/3 of original media volume). For MC-SUBs, this is the working volume of the SUB vessel (75% 
working volume).
cL: Compact multi-layer (e.g., HYPERStack, Corning); FBC: Fluidized bed centrifugation; L: Multi-layer (e.g., Cell factory systems (Nunc), CellSTACK (Corning); 
MC: Microcarrier-based single-use bioreactor; QC: Quality control; TFF: Tangential flow filtration. 
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Table 2. Equations of the downstream processing model.
COGDSP/dose 
1 COGDSP
dose
j C C C Cmat j
annual
lab j
annual
QC j
annual
dep j
a
=
∑ + + +, , , ,
nnual
ma j
annualC
Dannual
+ int,( )
Microcarrier removal with tangential flow filtration
2 Vfiltrate = Ai F tmax
3 Vmax = Vfiltrate + VMC
4 Cy V Vtotal in= / max
5
=













NTFF
Cytotal
Nfilter
Vmax
Vcy
6 Vwaste = (Vin per rig + Vprime per rig) - Vout per rig
7 CBag,Total = [(CBag,Vin per rig + CBag,Vout per rig + CBag,waste + 2CBag,prime per rig)NTFF] + CBag,Vout total
8 Ctubing,Total = (Ctubing,Feed + Ctubing,retentae + Ctubing,permeate)NTFF
9 C         = (CBag,Total + Cprime + Cfilter + Ctubing,total)Lannual
annual
mat,MC
10 C        = [(HtMCO)NTFF]Lannual
annual
lab,MC
Volume reduction with Tangential flow filtration
11
CFdesired= SinYVRYcryo
2X(Vin - VMC)
12
=
2X
Vout
SinYVRYcryo
13 F t
CF
N
CFactual
W
actual
Ai max
1
1




+






Vmax =
-
14
=Cytotal,(cell)
Vin - VMC
Vmax
15
Cytotal,(volume) = 
Sin
SM,i
Largest Cytotal from 14 and 15 set to Cytotal
16 VDF = (Vout per rigNW) + VHF + VHB
17 Vwaste = (Vin per rig + Vprime per rig + VDF) - Vout per rig 
18
=
−





+












1
1

tVR
Vin per rig
CFactual CFactual
NW
AiF
19 C        = (CBag,Total + Cprime + Cfilter + Cpump tubing,total + Ccflex tubing,total + CDF)Lannual
annual
mat,VR
20 C          = [(Cpump + Clap + CFH + CSB + Cchil + CBH + CBA + Cskid + Csens)NTFF] + Cweld
annual
equip,VR
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Materials & methods
Tool description
The decisional tool described in [5] was further devel-
oped to address the challenge of identifying the most 
cost-effective downstream processing and fill finish tech-
nologies and their sizes for cell therapies across a range 
of doses, demands and lot sizes. The model was created 
in C# with the .NET framework (Microsoft1 Visual 
Studio 2010, Microsoft Corporation, WA, USA) linked 
to Microsoft® Access (Microsoft® Corporation, WA, 
USA). The DSP bioprocess economics model together 
with the input database was utilized to establish pos-
sible process flowsheets taking into account key process 
and technology-specific limitations, and calculations for 
resource consumption and equipment sizing. The flow-
sheets were then analyzed by the optimization algorithm 
(Figure 2) to establish the optimal process, with output 
results established in the database. Key input parameters 
for DSP, were the number of cells and total volume post-
expansion and trypsinization; these are highlighted in 
Table 1. Once the optimal USP technology was fixed, 
the DSP cost of goods per dose (COG
DSP
/dose) was 
determined for a specific DSP flowsheet. For this analy-
sis, the COG
DSP
/dose was determined by the sum of the 
annual direct operating costs (i.e., materials, labor and 
QC) and indirect costs (facility-dependent depreciation 
Microcarrier removal with fluidized bed centrifugation 
21 CFMC = Vin/Vout
22
=
+ +






1 1 1
CFMCQHNchQNNchQSNCh
Vmax
(tmax - tR)
23 Vin per cy
tMC per cy
Vin per cy Vin per cy
QSNch QNNch CFMCQHNch
tR+ + +=
24
=NFBC,MC
Vin per cycleCytotal
VmaxNcy per rig
25 C        = CBag,Total + Cprime
annual
mat,MC
Cytotal estimated as in 14 and 15 above; labor cost estimated as in 
equation 10 with NFBC.
Volume reduction with fluidized bed centrifugation:
26
=
− −













+ +
1 1 1




CFMCQHNchQNNch
QN
QSNch
NWVBtmax
Vmax
tR
27 Vwash = (Vout per rigNW) + VHB
28
+ + + +






Vin per cytVR = Ncy per unit  =
Vin per cy Vin per cy NWVB
QSNch QNNch CFDesiredQHNch QN
tR
29 C        = (CBag,Total + Ccons + Cwash + Cprime)Lannual
annual
mat,VR
30 C          = [(CFBC + Cchil + CBH + Cskid)NFBC] + Cweld
annual
equip,VR
Vial filling precryopreservation
32
tf
N
H
cryo
vial
=
33 C       = (Cform + Cvial)Lannual
annual
mat,F
31 C        = (HtfONf)Lannual
annual
lab,F
34 C        = CFM + CFR + CSB
annual
equip,F
Table 2. Equations of the downstream processing model (cont.). 
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and maintenance costs) divided by the annual product 
output in number of doses/year (Equation 1 & Table 2). 
The overall optimization framework is summarized 
in Figure 2. The key equations used in the model are 
summarized in Table 2 and the nomenclature is provided 
in the Supplementary Material (see online at www.
futuremedicine.com/doi/full/10.2217/RME.15.29).
Case study setup
An industrially relevant case study was set up to inves-
tigate volume reduction (VR) and fill finish technolo-
gies for commercial allogeneic mesenchymal stromal 
cell (MSC) therapies. Volume reduction technologies 
investigated included tangential flow filtration of vari-
ous filter and single-use set-up sizes, and fluidized bed 
centrifugation sizes of different total volume capacities. 
Table 1, and Supplementary Tables A1 & A2 summarize 
the different volume reduction technologies evaluated in 
this study. A to F are used to distinguish between small-
to-large TFF units, by varying six filter sizes for tangen-
tial flow filtration (TFF; from 0.023 m2 [denoted in this 
study as TFF-A] to 1.15 m2, [referred to as TFF-F]). Dif-
ferent volume capacities for fluidized bed centrifugation 
(FBC) were also investigated. In this article, A and B 
are used to distinguish between small and large units of 
fluidized bed centrifugation. FBC-A has a smaller total 
volume capacity than FBC-B, in other words, 1 × 100 
ml chambers for FBC-A, (denoted as FBC-A [1ch]) to 
4 × 100 ml chambers (referred to as FBC-A [4ch]) and 
1× 1000 ml chambers in FBC-B (i.e., FBC-B [1ch]) 
to 6 × 1000 ml chambers in FBC-B [6ch]. Vial filling 
technologies (denoted here as Fill; also highlighted in 
Supplementary Tables A1 & A2), had varying vial fill-
ing capacities from 180 × 1 ml vials/h (referred to as 
Fill-A) to 10,800 × 1ml vials/h (denoted as Fill-D in 
this article). These tables were generated from litera-
ture sources and vendor communications, in addition 
to advice sought from industrial experts with respect 
to technology limits and process trade-offs. Examples 
of associated commercial names are in the footnotes or 
legends of Table 1 & Supplementary Table A1. The tool 
was run for different scenarios to investigate the impact 
of different doses ranging from 106 to 109 cells/dose, 
annual demands of 1000–500,000 doses/year, and lot 
sizes (50–10,000 doses/lot), in order to identify optimal 
volume reduction and vial filling technologies at differ-
ent doses, demands and lot size scenarios. Table 1, and 
Supplementary Tables A1 & A2 highlight the key process 
and cost assumptions of the model.
Key model constraints included a limit of one equip-
ment unit for volume reduction and washing per lot. 
This is a typical constraint in the well-established bio-
pharmaceutical industry due to validation concerns. 
This is particularly important for cell therapy where 
time for cell concentration can be limited to 4–8 h [8] 
to maintain cell viability. For some cell types, tighter or 
more relaxed time constraints may be required. Another 
key model constraint was to determine whether the 
target final concentration at the end of the flowsheet 
could be reached, taking into account minimum har-
vest volumes for the VR technology. The time allowed 
for formulation and completion of vial filling precryo-
preservation was set to 2 h [8] because of the limited 
time cells can spend in cryopreservation medium at 
room temperature. This 2-h time-limit assumes the use 
of DMSO as a cryopreservation buffer, but could differ 
if a different cryopreservation medium was used.
Results & discussion
Process limitations of downstream processing 
technologies for cell therapy
Figure 3A shows the maximum cell output attain-
able for planar and nonplanar expansion technologies 
considered in this article, when considering the maxi-
mum number of units that can possibly be handled 
in a single lot. The ideal number of volume reduction 
(VR) units was set to 1, and this was dependent on 
several factors including maximum cell and volume 
capacity of the technology, target final concentration, 
time constraints for this process step, flux for TFF 
and operational flowrates for FBC. As each individual 
cell expansion unit such as T-flasks or Cell Factories 
produces a different number of cells per unit volume, 
the average, (0.36 billion cells/l) was used to evaluate 
TFF and FBC. As in [5], the expansion technologies 
were given abbreviations such as ‘L’ to denote multi-
layer cell stacks or factories and ‘cL’ to denote compact 
multi-layer systems such as the Hyperstack (Corning, 
MA, USA). Figure 3A demonstrates that each expan-
sion technology spans one log of performance in terms 
of billion cells per lot before being outperformed by 
a newer technology. For microcarrier-based single-
use bioreactors and the current performance in terms 
of cells per milliliter in culture (about 0.5 million 
cells/ml), two logs are attainable for single-use biore-
actors (SUB) sizes spanning 20–2000 l; however, the 
maximum expected commercial lot size of 1013 cells is 
not attainable, as described in [5]. Under the VR tech-
nology and process conditions described in Table 1 and 
Supplementary Table A1, which includes a target con-
centration of 10 million cells/ml and a constraint of 
1 VR unit per lot, TFF can handle 3 billion cells (TFF-A 
with a 0.023 m2 membrane and smaller associated pro-
cess lines) to 152 billion cells per lot (TFF-F with a 
1.15 m2 membrane and larger associated process lines). 
Thus, for a target concentration of 10 million cells/ml, 
TFF is suitable for handling the maximum number 
of expansion units per lot for hollow fiber bioreactors, 
www.futuremedicine.com 599future science group
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10–50 layer bioreactors, five- to ten-layer vessels and 
12–36 layer compact vessels (note: automation allows 
a maximum of 320 vessels per lot). For smaller multi-
layer vessels, it is possible to use the smallest TFF, but 
the target final concentration would have to be lower 
than 10 million cells/ml. For automated planar vessels 
and microcarrier-based single-use bioreactors with a 
hypothetical pooled cell and volume load from eight 
2000 l bioreactors, it would also be possible to use TFF 
but more than one of the largest rigs (TFF-F) would 
be required to enable this. For FBC-A and FBC-B, the 
cell load limits per lot are 15–59 × 109 cells/lot and 
60–222 × 109 cells/lot, respectively. To enable FBC use 
for the maximum number of T-flasks, multi-layer ves-
sels and smaller compact multi-layer vessels, the tar-
get final concentration would have to be lowered for 
FBC-A [1ch] to less than 10 million cells/ml, and for 
the maximum number of automated multi-layer and 
compact multi-layer vessels, and the pooled load of 
eight SUBs, FBC-B [6ch] can be used but more than 
one would be required per lot.
For the dose, demand and lot size scenarios tested in 
the model, the number of 6 ml cryovials required per 
automated vial filling machine was plotted against cells 
per lot (Figure 3B). The number of cryovials required 
per optimal vial filling machine increased from 28 
vials at 50 million cells per lot, to 2084 vials per vial 
filling machine at 250 billion cells per lot. The optimal 
vial filling machine capacities are plotted in the second-
ary axis of Figure 3B and have capabilities from 180 1 ml 
vials per hour (Fill-A) that are able to handle the lower 
cells per lot in the time constraint of 2 h, to 10,800 vials 
per hour for the largest automated fill machine (Fill-D).
Cost–effectiveness of downstream processing 
technologies for cell therapy
Figure 4 addresses the overall optimal expansion, VR 
and vial filling technologies within the model’s num-
ber of unit constraints for each step in the process. The 
expansion results are very similar to [5] where for expan-
sion technologies the maximum number of planar 
expansion units that can be handled per lot is assumed 
to be 80 and the number of microcarrier-based SUBs is 
eight. The cell and volume outputs of optimal expan-
sion technologies of Figure 4 are detailed in Table 1. In 
this study, however, the overall DSP yield was assumed 
to be 68%, assuming an 85% VR yield and an 80% 
yield post thawing after cryopreservation. For processes 
including microcarrier-based SUBs, it was assumed that 
microcarrier removal resulted in a cell recovery of 90%, 
and hence the overall DSP yield was 61%. The optimal 
DSP technologies are based on optimal COG
DSP
/dose 
after finding the optimal USP technology based on 
COG
USP
/dose, in other words, for a fixed USP technol-
ogy. This analysis considered typical commercial num-
bers of lots ranging from 10 to 200 lots per year. Each 
individual matrix cell shows the optimal technologies 
for a specific demand and lot size, in addition to the 
number of units required, indicated by square brackets. 
Facility depreciation was also taken into account in the 
indirect costs of this analysis, and so there is variation 
in optimal cell expansion technologies at each cells/lot 
compared to [5]. At lower lot sizes for a dose of 106 cells, 
the demand is met by smaller expansion systems 
(Figure 4A). In these cases, TFF-A is the only option 
for cell washing and VR due to the lower minimum 
harvest volume allowed. In these cases however, the 
final possible cells per milliliter is also lower, in other 
words, 0.3 – 7 million cells/ml. For the smaller lot sizes 
and doses shown in Figure 4A there may be a possibil-
ity in achieving 10 million cells/ml if necessary instead 
of the lower targets theoretically achieved by the can-
didate technologies in our study using smaller systems 
used for concentrating lentiviral vectors, where it is pos-
sible to concentrate down to about 1 ml [15]. This would 
increase the scope of TFF even further. At a dose of 
106 cells, a lot size of 2500 doses/lot, the optimal tech-
nologies that meet the maximum number of units con-
straints for each technology and can achieve the final 
desired 10 million cells/ml and have the overall com-
bined total COG/dose is 9 cl-36 units or 6 L-40 units 
followed by FBC-A [1ch] and Fill-A because this is the 
only technology able to meet the target final concentra-
tion with one unit. Moving vertically down the matrix 
with increasing demand in doses/year, the difference in 
COG
DSP
/dose for alternate DSP technologies decreases. 
In situations where the COG/dose difference was less 
than 5%, the model determined that either technology 
was feasible and this is shown for example at a dose of 
107 cells (Figure 4B), a lot size of 500 doses/lot and a 
demand of 100,000 doses/year where both TFF-C and 
FBC-A [1ch] are equally competitive.
In general, moving horizontally across the matri-
ces solution space, as lot size increases, larger capacity 
VR technologies are required, for example, larger area 
TFF filter membranes or a greater number of cham-
bers for FBC or volume per chamber, all necessary for 
maintaining the one unit DSP constraint. At a dose of 
107 cells per patient and a lot size of 10,000 doses/lot 
(Figure 4B), the largest unit of TFF (TFF-F) is the 
optimal VR technology able to achieve the target final 
concentration with a single unit and this is followed 
by Fill-C. Figure 4C shows that at a dose of 108 cells 
and 2500 doses/lot, FBC-B is the clear winner as it 
is the only technology capable of meeting the num-
ber of units constraint of a single unit due to its larger 
cell and volume capacity. In our case study, filter areas 
of 0.023–1.15 m2 were investigated since these hollow 
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fiber systems are easily connected to sterile tubing and 
bags using GE ReadymateTM sterile systems. However, 
filters of 2.6–11.3 m2 are also available in the mar-
ket and can be provided in irradiated, sterile format 
in a ‘module, bag, tubing’ or MBT (KrosFlo® filters 
and KrosFlo® MAX filters from Spectrum Labs). All 
TFF units tested in the study feature as optimal solu-
tions with the exception of intermediates, TFF-B and 
TFF-E, only due to the incremental changes in cells 
per lot that we investigated in this study. For FBC-A 
either using one chamber to four chambers are opti-
mal with cycling for up to two cycles possible in some 
cases, for example, at a dose of 108 cells, a demand of 
50,000 doses per year and a lot size of 500 dose per 
lot. At a dose of 109 cells, (Figure 4D) and a lot size of 
500 doses per lot, in other words, 0.5 × 1011 cells per 
lot, although the optimal cell expansion technology are 
3 × 1000 l or 5 × 500 l microcarrier-based SUBs, none 
of the VR technologies are capable of meeting the one 
unit constraint as it would be necessary to use 3 units 
Figure 4. Optimal upstream and downstream technologies for allogeneic cell therapy manufacture across varying dose, demand 
and lot size scenarios. Optimal cell expansion, volume reduction and vial filling technologies across a matrix of demands and lot sizes 
for a mesenchymal stromal cell dose of (A) 106 cells, (B) 107 cells (C) 108 cells, (D) 109 cells. For cell expansion technologies, there was 
a preference for planar technologies unless the maximum number of planar units per lot constraint was exceeded. Each matrix cell 
shows the name of the optimal technology for a particular combination of demand and lot size. The number of DSP units is 1. The 
optimal option for each demand in terms of COGDSP /dose is highlighted in italics.
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of FBC-B with all six chambers to concentrate the 
pooled load from three SUBs within the 4-h time con-
straint, and this is represented by the light gray region 
in the matrix. Hence DSP bottlenecks are encountered 
before the USP bottleneck. The dark gray region at 
10,000 doses per lot is due to both the cell expansion 
Figure 5. Economies of scale as a (A–C) function of demand and (D–F) cells per lot for (A & D) COGDSP/year,  
(B & E) COGDSP/dose and (C & F) % COGDSP /dose. The results are shown for 1 unit of FBC-B and 1 unit of TFF-F, both 
later filled using Fill-D. In (A–C), a single mesenchymal stromal cell dose of 108 and a fixed lot size of 1000 doses 
per lot were assumed. For (D–F) a single mesenchymal stromal cell dose of 107 was assumed with lot size and 
demand varying. Filled circles represent total costs for tangential flow filtration (TFF), clear circles are total costs 
for fluidized bed centrifugation (FBC), filled triangles are indirect costs for TFF, clear triangles are costs for FBC, 
filled squares are direct costs for TFF and clear squares are direct costs for FBC. Planar cell expansion in all cases.
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technologies and DSP technologies not being able to 
meet the maximum number of unit constraints.
The optimal technology at each demand and dose 
is highlighted in italics in Figure 4. At lower doses of 
number of cells per patient (e.g., 106 cells), the optimal 
technology is more greatly influenced by the number 
of lots per year, such that direct costs decrease with 
decreasing number of lots, or increasing lot size and 
indirect costs are constant as there is no change in 
equipment. At the other end of the dose spectrum 
(e.g., 109 cells), where the same DSP technology is 
used, indirect costs are similarly constant, but direct 
costs do not decrease in proportion with decreasing 
number of lots per year due to a need to process an 
increasing number of cells per lot causing an increasing 
direct cost for every lot.
Key cost drivers for downstream processing 
technologies for cell therapy
Figure 5A–C assess the economies of scale achieved by an 
increasing market demand in doses per year via a fixed 
facility outputting an increasing number of lots per 
year or an increasing cells per lot. The example shown 
here is for a dose of 108 cells and a single lot size of 
1000 doses per lot. Figure 5A is shown in COG
DSP
/year. 
As expected direct costs increase with dose output 
and indirect costs are fixed with increasing demand. 
These trends are similar for TFF and FBC. Figure 5B 
shows that direct COG
DSP
/dose for both technologies 
is constant. In contrast, the indirect COG
DSP
/dose 
decreases with demand, as these costs are spread over 
an increasing number of lots per year (at a fixed lot 
size), resulting in an overall decrease in COG
DSP
/dose 
due to economies of scale. As anticipated, the indi-
rect COG
DSP
/dose represents a higher proportion of 
the total COG
DSP
/dose than the direct COG
DSP
/dose 
across all dose outputs, although the ratio of direct to 
indirect costs increases with demand for both technolo-
gies (Figure 5C). Figure 5D–F represent increasing cells 
per lot moving across a diagonal of the matrix at a dose 
of 107 cells, for a fixed number of lots per year of 50. 
Figure 5D & E illustrates that as cells per lot increases (by 
increasing lot size or scale of production), both direct 
and indirect costs increase, but the relative increase in 
indirect costs is much higher as larger equipment is 
required as scale of production increases. As the cells 
per lot increases, the scale of production increases and 
larger equipment are used to produce a greater amount 
of cells per lot and hence total COG
DSP
/dose overall 
and both direct and indirect COG
DSP
/dose decrease 
(Figure 5E). Thus, for a constant number of lots per 
year, the proportion of COG
DSP
/dose represented by 
indirect costs increases and those represented by direct 
costs decrease (Figure 5F).
Figure 6A & B show a comparison of the cost 
breakdown for TFF and FBC for a fixed demand of 
100,000 doses per year across different lot sizes (500 
and 10,000 doses per lot) for a dose of 107 cells/patient. 
Throughout, depreciation and maintenance dominate 
as FCI is considered as 23.67 × the total equipment 
purchase cost, where 23.67 is the Lang factor previously 
established for disposable systems [16]. At 500 doses per 
lot, beyond depreciation, QC costs dominate, followed 
by material costs for TFF and FBC-A. Labor costs are 
the lowest contributor to overall costs in these cases. At 
500 doses per lot, FBC-B cannot reach the target con-
centration factor of achieving 10 million cells per ml in 
the final vial due to its larger minimum harvest volume 
requirement brought about by its larger overall size and 
capacity, and hence it is not an option at this lot size. 
Overall, DSP technologies TFF-C with Fill-B and 
FBC-A [1ch] with Fill-B are optimal DSP technologies 
in terms of meeting the number of unit constraints and 
having the lowest COG
DSP
 per dose for a fixed cell load 
of 18 l of 7.5 billion cells from 5 cl-120 units. The dif-
ference in COG
DSP
/dose between both options is only 
6%. At 10,000 doses per lot, TFF-F followed by Fill-C 
is the optimal solution for COG
DSP
/dose (Figure 6B). At 
this lot size, depreciation is more significant due to the 
fact that there are fewer lots per year over which this 
depreciation can be spread. Since, FBC-A has a higher 
labor cost (1.7×) and a slightly higher depreciation and 
maintenance (1.2× greater) than TFF, TFF-F followed 
by Fill-C has a 21% lower COG
DSP
/dose than FBC-A 
[4ch, 2cy] which also requires two FBC units and is 
hence optimal. Unlike at 500 doses per lot, at 10,000 
doses per lot, FBC-B can reach the target concentra-
tion factor and hence is an option however, with Fill-C 
the overall COG
DSP
/dose is 26% higher than TFF with 
Fill-C. The detailed direct cost breakdown for TFF at 
500 doses per lot and 10,000 doses per lot are shown in 
Figure 6C & E. For FBC, Figure 6D & F show that similar 
to TFF, material costs are dominated by consumables 
rather than chemicals. On a per lot basis, QC costs 
dominate at 500 doses per lot whereas at 10,000 doses 
per lot, material costs are the main direct cost driver.
Improvements required in current DSP 
technologies for future demands
Figure 7A & B analyzes debottlenecking strategies to 
address the gray region in Figure 4D where none of the 
candidate VR technologies are able to meet the num-
ber of unit constraints and assesses how the number 
of TFF-F and FBC-B units can be reduced to 1 unit. 
Figure 7A examines changing key VR parameters at a 
demand 50,000 doses per year and a lot size of 2500 
doses per lot, and a dose of 109 cells/patient, to achieve 
the desired 1 DSP unit per lot constraint. For TFF, 
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the area of the bubbles represents the area of the filter 
membranes, whereas for FBC, the area of the bubbles 
represents the volume into the VR step. The base case 
is shown on the right hand side of the graph with a 
process time of 4 h. With a 1.15 m2 membrane and a 
volume VR process time limitation of 4 h, 22 TFF rigs 
are needed to process the pooled load from six 2000L 
SUBs. For FBC processing this total load would require 
9 FBC-B units. The left hand side of the graph has an 
increased process time constraint of 8 h, and explores 
the use of future rigs able to accommodate 3 filters with 
filter cartridge areas that are up to four times larger 
than the current maximum. For example, using three 
4.6 m2 membranes with this increased process time 
Figure 6.  Cost breakdowns and drivers for COGDSP/dose. Comparison between TFF and FBC for a fixed demand of 
100,000 doses/year and across different lot sizes for a dose of 107 cells in terms of (A) COGDSP structure at 500 doses 
per lot and 200 lots per year (B) 10,000 doses per lot and ten lots per year. Detailed direct COGDSP breakdown at 
500 doses per lot for (C) TFF-C (D) FBC-A [2ch] both with Fill-B, and at 10,000 doses per lot (E) TFF-F (F) FBC-B [3ch] 
both with Fill-C. 
FCB: Fluidized bed centrifugation; QC: Quality control; TFF: Tangential flow filtration.
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Figure 7.  Improvements required in current downstream processing technologies for future demands. (A) Bubble 
plot to depict the effect of changing a combination of process parameters to achieve an ideal of 1 downstream 
unit for a demand of 50,000 dose per year, a lot size of 2500 doses per lot and a dose of 109. (B) Elimination of the 
light gray region in the matrices of Figure 5 and the impact of increasing process time to 8 h for volume reduction 
and/or staggering the load from bioreactors on optimal downstream processing technologies. 
FCB: Fluidized bed centrifugation; TFF: Tangential flow filtration.
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would allow TFF to be used. Alternatively, three 2.3 m2 
filter cartridges at this increased process time, and half 
the load processed per unit time by staggered upstream 
processing (USP) would also give rise to 1 unit. Using 
the same principle for FBC, a fivefold decrease in cell 
load to 1.8 l at the increased process time constraint of 
8 h would also allow 1 DSP unit to be achieved.
Figure 7B shows how 1 VR unit can be achieved in 
DSP for all gray regions in Figure 4D where the maxi-
mum number of SUBs per lot is not violated. This 
analysis shows that increasing the time allowed for this 
VR step to 8 h and/or staggering bioreactors allows 
1 VR unit per lot to be achieved. At a dose of 109 cells 
and 500 doses per lot, a pooled load from five 500L bio-
reactors can be handled by 1 FBC-B unit and 3 Fill-D 
units, in other words, a critical cells per lot input of 870 
billion cells for a cell density load of 0.46 billion cells/l. 
Alternatively, if this load was to be staggered also, then a 
single FBC-B unit and 1 Fill-D unit would be possible. 
TFF can handle up to 152 billion cells which translate 
into processing up to 330 l per unit in a 4-h window or 
305 billion cells and 662 l in an 8-h window. FBC can 
handle 346 billion cells and 752 l or 733 billion cells 
and 1593 l in a 4 or 8 h, respectively with a single unit.
Target cost of goods
Figure 8A shows acceptable COG per dose for concen-
trating a cell load from planar vessels (10, 40 or 120 layer 
Figure 8.  Target cost of goods and upstream to downstream COG ratios. (A) COG as a percentage of sales for a 
dose of a billion cells per patient, a demand of 10,000 doses per year and a lot size of 50 doses per lot for various 
cell expansion technologies. DSP is an average for tangential flow filtration and fluidized bed centrifugation 
followed by filling as these COGDSP values were similar for this scenario. The black bar indicates a potential target 
value of 15% for COG as% sales. (B) Variation in the percentage of USP and DSP COG/dose as a function of 
increasing cells per lot for a planar cell expansion process and for a (C) microcarrier-based single-use bioreactor 
cell expansion process. The target final product concentration was lowered to enable the MC-SUB process to be 
feasible in C. 
DSP: Downstream processing; USP: Upstream processing.
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vessels) and microcarrier-based SUBs at a dose of 109 
cells per patient, for a demand of 10,000 doses per year 
a lot size of 50 doses per lot. Regardless of the expansion 
technology, USP dominated the total COG, represent-
ing about 80% of the total COG/dose for this cells/lot 
value. A target COG as % sales value of 15% was chosen 
assuming allogeneic cell therapies will have gross mar-
gins in line with biologics to recover R&D and sales 
and marketing costs with attractive profit margins [1]. 
Assuming reimbursement values and hence sales values 
could be in the order of US$40,000, this would result 
in COG as percentage sales value of 21% for planar 
(i.e., US$8400/dose) and 11% for microcarrier-based 
SUBs (i.e., US$4400/dose). This analysis indicates that 
for this scenario, only MC-SUBs would be an acceptable 
option for this target COG as percentage sales.
Upstream to downstream COG ratios
The analysis explored whether COG values for alloge-
neic therapies are dominated by USP or DSP costs and 
how this is affected by increasing cells per lot for a pla-
nar and microcarrier-based SUB process. Figure 8B & C 
shows that for both planar and MC-SUB technologies, 
as cells per lot increases, the proportion of COG
USP
 
increases and COG
DSP
 decreases. Hence it is important 
to consider the cells per lot when determining COG
USP
: 
COG
DSP
 ratios since they vary with scale. Figure 8B 
shows that COG
USP
: COG
DSP
 split is 45:55 at 109 cells 
per lot to 80:20 at 1011 cells per lot. Since upstream 
production is cheaper for MC-SUBs, Figure 8C shows 
that at 1 × 109 cells/lot COG
USP
: COG
DSP
 split is 20:80, 
but this shifts to 50:50 at 1011 cells/lot. The cost dis-
tribution between USP and DSP for microcarrier-SUB 
processes is similar to the traditional biopharmaceuti-
cal industry where for recombinant protein production 
DSP normally represents 50–80% of the total COG 
[17]. Our analysis thus, highlights that the COG
USP
: 
COG
DSP
 ratio depends on both the upstream route 
(planar vs microcarrier-SUB) and the desired cells/
lot and hence these factors must be considered when 
identifying where to focus process development efforts.
Conclusion
Deviations from the process platform investigated in 
this paper may occur in some cases and impact the eco-
nomics of processes, such as: addition of an irradiation 
step in DSP for MSCs in order to preserve their immu-
nosuppressive potential and inhibit their clonogeneic 
capacity [18]; the replacement of fetal bovine serum with 
human platelet lysate in cell culture and the subsequent 
impact on the DSP washing steps[19], and alterations 
to cryopreservation and thawing logistics following 
reports suggesting that there is reduced immunodula-
tory function of cryopreserved MSCs upon thawing 
[19,20]. Process economics analyses will help identify if 
these deviations have a significant impact on the overall 
economic feasibility of competing strategies.
Future perspective
Detailed process economics understanding as pre-
sented here provides visibility of the cost drivers, 
opportunities for cost reduction and allows the most 
promising strategies to be prioritized for further explo-
ration. The upstream and downstream processing 
Executive summary
A tool to identify the most cost-effective process flowsheets for allogeneic cell therapies
•	 A decisional tool to identify the most cost-effective process flowsheets for allogeneic cell therapies 
(mesenchymal stromal cells) across a range of production scales was developed.
•	 Bioprocess economics was integrated with optimization to assess the competitiveness of cell expansion 
technologies (i.e., planar or bioreactor) and single-use and scalable volume reduction technologies (VR).
Volume reduction technologies & downstream processing
•	 The tool predicted that tangential flow filtration was generally more cost effective for the lower cells per lot 
obtained in planar technologies and that fluidized bed centrifugation became the only feasible option for 
handling large bioreactor outputs.
•	 Commercial lot sizes greater than 500 billion cells per lot required multiple large bioreactors and was found to 
lead to VR bottlenecks.
•	 Debottlenecking strategies explored included staggering bioreactors and doubling the time constraint for VR.
•	 Downstream processing contribution to the COG per dose was found to be more significant at smaller scales 
with observed ranges of 20–55% using planar upstream technologies, and 50–80% using bioreactors.
Conclusion
•	 For lower cells per lot achieved in planar technologies, tangential flow filtration was the more cost-effective 
option.
•	 For higher cells per lot achieved in large single-use bioreactors, fluidized bed centrifugation became the only 
feasible option.
•	 Only bioreactor-based flowsheets coupled with either filtration or centrifugation would allow for a successful 
business model for high-dose scenarios.
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bottlenecks identified highlight the technical innova-
tion and optimization required to adapt existing tech-
nologies for cell therapies so as to bridge the gaps con-
straining large-scale production. The sector’s progress 
is indicative that it will be able to move toward higher 
yielding, more robust and scalable manufacturing 
processes and that this will result in more cost-effec-
tive production of allogeneic cell therapies and hence 
feasible business models. Yet the benefits of early iden-
tification of cost effective and scalable manufacturing 
processes could be critical to achieving a sustainable 
business model. Companies face challenges handling 
commercial demands that require a switch in manu-
facturing technologies especially since cell character-
ization assays may make comparability difficult. Thus 
the cell therapy community and evolving develop-
ment and regulatory pathway for mesenchymal stro-
mal cells have an important role to play in the future 
economics for allogeneic cell therapy manufacturing.
A future paper from the authors will present an 
analy sis of the consequences of process changes pre- 
and post-approval not only on cost of goods but also 
on the cost and time of drug development as well as 
the overall profitability over a drug’s path to market.
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